Frequently Asked Questions
Welcome to the Kazmira FAQ Center – your trusted source for understanding prescription-strength cannabinoid therapy. Whether you’re a patient exploring treatment, a provider seeking clarity, or a partner curious about how it all works, this page is your clinical companion. Every answer is grounded in science, regulatory transparency, and pharmacy standards.
Cannabidiol (CBD) is a non-psychoactive compound derived from the cannabis plant. It interacts with the body’s endocannabinoid system (ECS), which helps regulate inflammation, pain, stress response, and mood.
No. CBD is just one of over 100 cannabinoids found in cannabis. THC causes a “high.” CBD does not. Kazmira’s compounds are 100% THC-free.
Yes. CBD is generally well tolerated, even at high doses. Side effects are rare but may include drowsiness, GI discomfort, or low blood pressure.
No. CBD is not addictive, habit-forming, or associated with withdrawal symptoms. It’s being studied as a support agent for addiction recovery.
Because Kazmira’s compounds are custom-made, high-dose therapies intended for clinical use—not consumer-grade wellness. This is real medicine, not a retail product.
This depends on your provider’s guidance. Kazmira does not currently offer pediatric formulations.
No. Kazmira formulations contain no THC, which is the cannabinoid most drug tests detect.
No. High-dose CBD isolate has been shown to be clinically effective without THC. While the “entourage effect” is commonly discussed in cannabis circles, most peer-reviewed studies on anxiety, chronic pain, and PTSD use CBD isolate, not full-spectrum products.
Kazmira’s therapies are THC-free, prescription-only, and compounded to therapeutic isolate doses – between 100–450 mg/day – to match real patient needs without psycho-activity, dispensary sourcing, or drug test risk.
We are not a brand. We are a 503A compounding pharmacy creating high-purity, prescription-only CBD therapies tailored to medical conditions.
We currently support therapies for:
- Neurological health (PTSD, anxiety, depression, dementia)
- Pain management (arthritis, fibromyalgia, chronic back pain)
- Addiction support (opioid and alcohol use disorders)
Typical daily doses range from 100 mg to 450 mg, though some cases may warrant higher or one-time titrated doses. Your provider decides.
Our most common form is a sublingual tincture. Other formats like creams, softgels, and capsules may be available upon clinical request.
It is Kazmira’s pharmaceutical-grade CBD isolate, refined under ICH Q7 GMP standards to ensure 0.0% THC and maximum purity.
No. Kazmira products are compounded based on individual prescriptions and are not mass-manufactured or FDA-approved for general sale.
A licensed facility where pharmacists create personalized medications prescribed for a specific patient. Kazmira is licensed under federal and state pharmacy laws.
503A pharmacies prepare prescriptions on a per-patient basis. They are regulated under Section 503A of the Federal Food, Drug, and Cosmetic Act.
- 503A = patient-specific, clinical prescriptions.
- 503B = bulk production for hospitals and clinics (like outsourcing facilities).
Reasons include allergy to commercial fillers, discontinued products, non-standard dosing needs, or alternative dosage formats.
Your provider customizes your formulation based on:
- Condition and treatment goals
- Weight and age
- Medication profile
- History of tolerability
Yes. Dosage and format can be modified based on your provider’s assessment and response to treatment.
503A-compounded CBD is legal under federal law, but some states have additional rules. Contact us to confirm licensure in your area.
No. CBD isolate with 0.0% THC is not a controlled substance.
No. Like all compounded medications, these are prepared under pharmacy law but not individually approved by the FDA.
Yes. Kazmira operates under USP <795>, <797> and ICH Q7 GMP standards for non-sterile compounding.
Yes. COAs for active ingredients are available upon request.
Yes. Most patients are eligible for HSA or FSA reimbursement. Contact your provider or benefits administrator to confirm.
It can be. However, CBD may interact with drugs including:
- Antidepressants
- Antiepileptics
- Opioids
- Antifungals
Your provider and our pharmacy will review your med list.
If you are on high-dose therapy or have liver issues, your provider may order labs (typically 4–6 weeks post-initiation).
Licensed prescribers including MDs, DOs, NPs, PAs, and dentists.
No. Any licensed provider can prescribe to Kazmira’s pharmacy. We provide onboarding support if they are unfamiliar.
Visit our [Partner Providers] or [Provider Onboarding] page and schedule a discovery call.
Yes. We provide:
- Custom Rx forms
- Dosing algorithms
- Titration logic
- Pharmacist consults
Yes. Our pharmacists are happy to collaborate with PCPs, specialists, and care teams.
Book with a Kazmira-affiliated or your own provider. They send the prescription, we do the rest.
No. Your therapy is shipped directly to your door.
Most orders ship in 1–3 business days after prescription receipt.
We send reminders and refill requests can be submitted by you or your provider.
Yes—ask your provider to submit a new order to our pharmacy.
You receive:
- Your compounded medication
- Dosing instructions
- A pharmacy insert
Yes. All deliveries are plain-labeled for patient privacy.
No. Store at room temperature in a dry, dark place.
- It is not marijuana
- It does not get you high
- It is not habit-forming
- It is not recreational
- It is not the same as dispensary products
- It is not meant to replace emergency care
Still Have Questions?
Use our contact form to reach a Kazmira team member or explore our condition-specific pages for more information.